BioLight is a life science investment company traded on the Tel Aviv Stock Exchange (TASE).
BioLight Israeli Life Sciences Investments Ltd. is a holding company engaged, through its subsidiaries, in various fields of research and development of pharmaceuticals and medical products and devices. The company was founded in 2005 and as of April 21, 2011 a group led by Mr. Israel Makov gained control in the company introducing a new approach of value creation through knowledge synergies (the clusters approach).
In July 2011 M.H Pharmaceutical Limited, owned by Mr. Dilip Shanghvi, CEO of Sun Pharmaceuticals Industries Ltd invested NIS 10.5M in BioLight, for a 17% stake.
BioLight recognized and launched a unique business model of a cluster-based value creation, resulting from the sharing of knowledge between companies (knowledge synergies) that deal with common medical areas and stipulations. The model is based on a combination of activities dealing with one disease area that is looked at from different angles of treatment: Diagnostics, imaging, screening, Pharmaceutical drugs, Drug delivery methods, medical devices, and more, all under one cluster. This approach will yield a large and focused company with extensive familiarity with the specific disease area, the market & competition. Such a cluster will lead the medical field, which will fabricate unique solutions and true innovation thus attracting the cooperation of leading pharmaceutical companies in and outside the specific medical field.
